ViiV In-Licenses Third-Gen HIV Targeting Compound From Shionogi

by Vandana Singh, Benzinga Editor

September 28, 2021 10:05 AM | 1 min read |

ViiV Healthcare, majority-owned by GlaxoSmithKline plc GSK, Pfizer Inc PFE, and Shionogi, has announced an exclusive collaboration and license agreement with Shionogi & Co Ltd for S-365598 for use in ultra long-acting HIV regimens.
S-365598 is a third-generation integrase strand transfer inhibitor with the potential for regimens with three months or longer dosing intervals.
Under the agreement terms, ViiV Healthcare will make an upfront payment of £20 million to Shionogi, £15 million as milestone payments, and royalties on net sales.
Shionogi will contribute to development costs up to an annual maximum.
First-in-human trials are slated for 2023.
Price Action: PFE stock is down 1.94% at $42.73, and GSK stock is down 1.31% at $38 during the market session on the last check Tuesday.

Posted In: Biotech News Health Care Contracts Movers Trading Ideas General Briefs HIV treatment

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.